https://www.selleckchem.com/pr....oducts/vps34-inhibit
Therefore, close monitoring for atherosclerotic disease progression is warranted in patients on immunotherapy. Nivolumab has been linked with dysregulation of immune responses including enhanced T cell activity, which is implicated in CAD. The timing of nivolumab therapy and presentation with non ST elevation myocardial infarction in this patient suggests a serious T cell-driven medication adverse effect. Therefore, close monitoring for atherosclerotic disease progression is warranted in patients on immunotherapy. Coordination
Like
Comment
Share
